SERTINDOLE - search results

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ketoconazole 200mg tablets

hra pharma uk ltd - ketoconazole - tablet - 200mg

haldol 5 mg

j-c health care ltd - haloperidol - tablets - haloperidol 5 mg - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Israel - English - Ministry of Health

haldol 2 mgml drops

j-c health care ltd - haloperidol - solution (oral) - haloperidol 2 mg/ml - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nortriptyline 25mg tablets

de pharmaceuticals - nortriptyline hydrochloride - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nortriptyline 10mg tablets

de pharmaceuticals - nortriptyline hydrochloride - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nortriptyline 25mg tablets

de pharmaceuticals - nortriptyline hydrochloride - oral tablet - 25mg